Search

Your search keyword '"Andrade, R.J."' showing total 192 results
Start Over Author "Andrade, R.J."
192 results on '"Andrade, R.J."'

2. Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

Author

Lucena, M.I., Villanueva-Paz, M., Alvarez-Alvarez, I., Aithal, G.P., Björnsson, E.S., Cakan-Akdogan, G., Cubero, F.J., Esteves, F., Falcon-Perez, J.M., Fromenty, B., Garcia-Ruiz, C., Grove, J.I., Konu, O., Kranendonk, M., Kullak-Ublick, G.A., Miranda, J.P., Remesal-Doblado, A., Sancho-Bru, P., Nelson, L., Andrade, R.J., Daly, A.K., and Fernandez-Checa, J.C.

Published
2024
Full Text
View/download PDF

3. Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry

Author

Slooter, C.D., Brand, F.F. van den, Lleo, A., Colapietro, F., Lenzi, M., Muratori, P., Kerkar, N., Dalekos, G.N., Zachou, K., Lucena, M.I., Robles-Díaz, M., Zeo-Sánchez, D.E. Di, Andrade, R.J., Montano-Loza, A.J., Lytvyak, E., Lissenberg-Witte, Birgit I., Maisonneuve, P., Bouma, G., Macedo, G., Drenth, J.P.H., Liberal, R., Boer, Y.S. de, Slooter, C.D., Brand, F.F. van den, Lleo, A., Colapietro, F., Lenzi, M., Muratori, P., Kerkar, N., Dalekos, G.N., Zachou, K., Lucena, M.I., Robles-Díaz, M., Zeo-Sánchez, D.E. Di, Andrade, R.J., Montano-Loza, A.J., Lytvyak, E., Lissenberg-Witte, Birgit I., Maisonneuve, P., Bouma, G., Macedo, G., Drenth, J.P.H., Liberal, R., and Boer, Y.S. de

Abstract

Contains fulltext : 305452.pdf (Publisher’s version ) (Closed access), BACKGROUND AND AIMS: The International Autoimmune Hepatitis Group retrospective registry (IAIHG-RR) is a web-based platform with subjects enrolled with a clinical diagnosis of autoimmune hepatitis (AIH). As prognostic factor studies with enough power are scarce, this study aimed to ascertain data quality and identify prognostic factors in the IAIHG-RR cohort. METHODS: This retrospective, observational, multicenter study included all patients with a clinical diagnosis of AIH from the IAIHG-RR. The quality assessment consisted of external validation of completeness and consistency for 29 predefined variables. Cox regression was used to identify risk factors for liver-related death and liver transplantation (LT). RESULTS: This analysis included 2559 patients across 7 countries. In 1700 patients, follow-up was available, with a completeness of individual data of 90% (range: 30-100). During a median follow-up period of 10 (range: 0-49) years, there were 229 deaths, of which 116 were liver-related, and 143 patients underwent LT. Non-White ethnicity (HR 4.1 95% CI: 2.3-7.1), cirrhosis (HR 3.5 95% CI: 2.3-5.5), variant syndrome with primary sclerosing cholangitis (PSC) (HR 3.1 95% CI: 1.6-6.2), and lack of complete biochemical response within 6 months (HR 5.7 95% CI: 3.4-9.6) were independent prognostic factors. CONCLUSIONS: The IAIHG-RR represents the world's largest AIH cohort with moderate-to-good data quality and a relevant number of liver-related events. The registry is a suitable platform for patient selection in future studies. Lack of complete biochemical response to treatment, non-White ethnicity, cirrhosis, and PSC-AIH were associated with liver-related death and LT.

Published
2024

4. P16-38: A systematic review of control compounds tested for validation of Drug-Induced Liver Injury (DILI) in vitro models

Author

Segovia-Zafra, A., primary, Villanueva-Paz, M., additional, Serras, A.S., additional, Matilla-Cabello, G., additional, Bodoque, A., additional, Di Zeo-Sánchez, D.E., additional, Niu, H., additional, Álvarez-Álvarez, I., additional, Godek, S., additional, Milisav, I., additional, Fernández-Checa, J.C., additional, Lucena, M.I., additional, Cubero, F.J., additional, Miranda, J.P., additional, Nelson, L., additional, and Andrade, R.J., additional

Published
2023
Full Text
View/download PDF

5. Incidence and predictors of hepatocellular carcinoma in autoimmune hepatitis: A multicenter international study

Author

Colapietro, F., primary, Maisonneuve, P., additional, Lytvyak, E., additional, Beuers, U., additional, Verdonk, R., additional, van der Meer, A., additional, van Hoek, B., additional, Kuiken, S.J., additional, Brouwer, H., additional, van der Wouden, E.J., additional, Muratori, P., additional, Aghemo, A., additional, van den Berg, A., additional, Dalekos, G. N, additional, Robles, M., additional, Andrade, R.J., additional, Montano-Loza, A.J., additional, van den Brand, F.F., additional, Slooter, C.D., additional, Macedo, G., additional, Liberal, R., additional, de Boer, Y., additional, and Lleo, A., additional

Published
2023
Full Text
View/download PDF

8. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

Author

Montano-Loza, A.J., Ronca, V., Ebadi, M., Hansen, B.E., Hirschfield, G., Elwir, S., Alsaed, M., Milkiewicz, P., Janik, M.K., Marschall, H.U., Burza, M.A., Efe, C., Caliskan, A.R., Harputluoglu, M., Kabacam, G., Terrabuio, D., Onofrio, F.D., Selzner, N., Bonder, A., Pares, A., Llovet, L., Akyildiz, M., Arikan, C., Manns, M.P., Taubert, R., Weber, A.L., Schiano, T.D., Haydel, B., Czubkowski, P., Socha, P., Oldak, N., Akamatsu, N., Tanaka, A., Levy, C., Martin, E.F., Goel, A., Sedki, M., Jankowska, I., Ikegami, T., Rodriguez, M., Sterneck, M., Weiler-Normann, C., Schramm, C., Donato, M.F., Lohse, A., Andrade, R.J., Patwardhan, V.R., Hoek, B. van, Biewenga, M., Kremer, A.E., Ueda, Y., Deneau, M., Pedersen, M., Mayo, M.J., Floreani, A., Burra, P., Secchi, M.F., Beretta-Piccoli, B.T., Sciveres, M., Maggiore, G., Jafri, S.M., Debray, D., Girard, M., Lacaille, F., Lytvyak, E., Mason, A.L., Heneghan, M., Oo, Y.H., and Int Autoimmune Hepatitis Grp IAIHG

Subjects
Adult, Male, Hepatology, liver transplantation, recurrent disease, autoimmune liver disease, graft survival, Mycophenolic Acid, survival, Hepatitis, Autoimmune, Recurrence, Risk Factors, Immunoglobulin G, Humans, Female, Immunosuppressive Agents
Abstract

Background & Aims: Autoimmune hepatitis can recur after liver transplantation (LT), though the impact of recurrence on patient and graft survival has not been well characterized. We evaluated a large, international, multicenter cohort to identify the probability and risk factors associated with recurrent AIH and the association between recurrent disease and patient and graft survival.Methods: We included 736 patients (77% female, mean age 42 +/- 1 years) with AIH who underwent LT from January 1987 through June 2020, among 33 centers in North America, South America, Europe and Asia. Clinical data before and after LT, biochemical data within the first 12 months after LT, and immunosuppression after LT were analyzed to identify patients at higher risk of AIH recurrence based on histological diagnosis.Results: AIH recurred in 20% of patients after 5 years and 31% after 10 years. Age at LT

Published
2022

9. Therapeutic management of idiosyncratic drug-induced liver injury and acetaminophen hepatotoxicity in the paediatric population: a systematic review

Author

Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Niu, H.; Atallah, E.; Alvarez-Alvarez, I.; Medina-Caliz, I.; Aithal, G.P.; Andrade, R.J.; Lucena, M.I., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), Koç University Hospital, School of Medicine, Arıkan, Çiğdem (ORCID 0000-0002-0794-2741 & YÖK ID 240198), Niu, H.; Atallah, E.; Alvarez-Alvarez, I.; Medina-Caliz, I.; Aithal, G.P.; Andrade, R.J.; Lucena, M.I., Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM), Koç University Hospital, and School of Medicine

Abstract

Introduction: Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF). The evidence for treatment of DILI in children is scarce. Objective We aimed to comprehensively review the available literature on the therapies for both acetaminophen overdose (APAP) and idiosyncratic DILI in the paediatric population. Methods: we included original articles conducted in a paediatric population (< 18 years) in which a therapeutic intervention was described to manage APAP or idiosyncratic DILI. Findings were summarized based on age groups (preterm newborn neonates, term and post-term neonates, infants, children and adolescents). Results: overall, 25 publications (fifteen case reports, six case series and four retrospective cohort studies) were included, including a total of 140 paediatric DILI cases, from preterm newborn neonates to adolescents. N-acetylcysteine was used to treat 19 APAP cases. N-acetylcysteine (n = 14), ursodeoxycholic acid (n = 3), corticosteroids (n = 31), carnitine (n = 16) and the combination of glycyrrhizin, reduced glutathione, polyene phosphatidylcholine and S-adenosylmethionine (n = 31) were the therapeutic options for treating idiosyncratic DILI. The molecular adsorbent recirculating system was used in the management of either APAP (n = 4) or idiosyncratic DILI (n = 2), while 20 paediatric ALF cases received continuous renal replacement therapy. Conclusions: this systematic review identified DILI in the paediatric population who have received specific treatment. These interventions appear to be mainly extrapolated from low-quality evidence from the adult population. Thus, there is a need for high-quality studies to test the efficacy of known and novel therapies to treat DILI specifically addressed to the paediatric population., European Union (EU); Instituto de Salud Carlos III (ISCIII); Fondo Europeo de Desarrollo Regional-FEDER; Consejería de Salud de Junta de Andalucía; Junta de Andalucia; COST Action; Prospective European Drug-Induced Liver Injury Network; Agencia Española del Medicamento; CIBERehd; Plataforma ISCIII Ensayos Clínicos; Sara Borrell; ISCIII

Published
2022

12. Advancing the global public health agenda for NAFLD: a consensus statement

Author

Lazarus, J.V. Mark, H.E. Anstee, Q.M. Arab, J.P. Batterham, R.L. Castera, L. Cortez-Pinto, H. Crespo, J. Cusi, K. Dirac, M.A. Francque, S. George, J. Hagström, H. Huang, T.T.-K. Ismail, M.H. Kautz, A. Sarin, S.K. Loomba, R. Miller, V. Newsome, P.N. Ninburg, M. Ocama, P. Ratziu, V. Rinella, M. Romero, D. Romero-Gómez, M. Schattenberg, J.M. Tsochatzis, E.A. Valenti, L. Wong, V.W.-S. Yilmaz, Y. Younossi, Z.M. Zelber-Sagi, S. Åberg, F. Adams, L. Khatry, M.S.A. Naamani, K.A. Murillo, O.A. Allen, A.M. Alnaser, F. Alqahtani, S.A. Alswat, K. Alvaro, D. Andrade, R.J. Arrese, M. Awuku, Y.A. Ayesha, M. Baatarkhuu, O. Bakieva, S. Basu, R. Bataller, R. Bedri, S. Bosi, E. Bourliere, M. Bruha, R. Bugianesi, E. Burra, P. Buti, M. Byrne, C.D. Calleja, J.L. Carrieri, P. Carter, F. Fernandez, M.I.C. Castillo-Lopez, G. Castro-Narro, G.E. Chan, H.L.Y. Chan, W.-K. Chang, Y. Colombo, M. Coppell, K.J. Corey, K. Craxi, A. Cryer, D. Dassanayake, A. Martins, A.A.S. de Ledinghen, V. DelPrato, S. Demaio, A. Desalegn, H. Dillon, J. Duseja, A. Dorairaj, P. Ekstedt, M. El Kassas, M. Elsanousi, O.M. Esmat, G. Fan, J.-G. Farpour-Lambert, N. Flisiak, R. Fouad, Y. Fuchs, M. Gani, R.A. Gerber, L. Ghazinyan, H. Gheorghe, L. Goh, G.B.-B. Grønbæk, H. Gulnara, A. Hamid, S. Hebditch, V. Hickman, I.J. Hocking, S.L. Hunyady, B. Idilman, R. Isakov, V.A. Jamal, M.H. Jepsen, P. Iskandar, N.J. Song, M.J. Sudhamshu, K.C. Kakizaki, S. Kalamitsis, G. Kanwal, F. Kao, J.-H. Kaplan, L. Kawaguchi, T. Khader, Y. Kim, S.U. Kodjoh, N. Koek, G. Koike, K. Komas, N.P. Korenjak, M. Kugelmas, M. Labidi, A. Lange, N.F. Lavine, J.E. Lazo, M. Lee, N. Lesmana, C.R.A. Liu, C.-J. Long, M.T. Lopez-Jaramillo, P. Malekzadeh, R. Mahtab, M.A. Marchesini, G. Marinho, R. Vázquez, S.E.M. Mateva, L. Nlombi, C.M. Melin, P. Mikolasevic, I. Milovanovic, T. Musso, C. Nakajima, A. Nava, E. Nersesov, A.V. Nikolova, D. Norris, S. Novak, K. Oben, J. Ong, J.P. Onyekwere, C. Papatheodoridis, G. Paruk, I. Patel, K. Macedo, M.P. Penha-Gonçalves, C. Figueroa, M.P. Hofmann, W.P. Petta, S. de Oliveira, C.P.M.S. Puri, P. Pan, C.Q. Rac, M. Ralston, J. Ramji, A. Razavi, H. Alvares-da-Silva, M.R. Roberts, S. Roden, M. Rose, T. Rouabhia, S. Rovere-Querini, P. Rowe, I.A. Sadirova, S. Salupere, R. Saparbu, T. Sayegh, R. Sebastiani, G. Seki, Y. Selmo, J. Serme, A.K. Shaw, J.E. Shenoy, T. Sheron, N. Shibolet, O. Silva, M. Skrypnyk, I. Socha, P. Soriano, J. Spearman, C.W. Sridharan, K. Suárez, J.J. Sheriff, D.S. Sung, K.-C. Swain, M. Tacke, F. Taheri, S. Tan, S.-S. Tapper, E.B. Yki-Järvinen, H. Thiele, M. Shawa, I.T. Tolmane, I. Torres, E.A. Trauner, M. Treeprasertsuk, S. Turcanu, A. Valantinas, J. Vesterhus, M. Waked, I. Wild, S.H. Willemse, J. Wong, R.J. Xanthakos, S. Young, D.Y. Yu, M.-L. Zheng, K.I. Zeybel, M. Zheng, M.-H. the NAFLD Consensus Consortium

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. © 2021, Springer Nature Limited.

Published
2022

13. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

Author

Stephens, Camilla, primary, Robles-Diaz, Mercedes, additional, Medina-Caliz, Inmaculada, additional, Garcia-Cortes, Miren, additional, Ortega-Alonso, Aida, additional, Sanabria-Cabrera, Judith, additional, Gonzalez-Jimenez, Andres, additional, Alvarez-Alvarez, Ismael, additional, Slim, Mahmoud, additional, Jimenez-Perez, Miguel, additional, Gonzalez-Grande, Rocio, additional, Fernández, M. Carmen, additional, Casado, Marta, additional, Soriano, German, additional, Román, Eva, additional, Hallal, Hacibe, additional, Romero-Gomez, Manuel, additional, Castiella, Agustin, additional, Conde, Isabel, additional, Prieto, Martin, additional, Moreno-Planas, Jose Maria, additional, Giraldez, Alvaro, additional, Moreno-Sanfiel, J. Miguel, additional, Kaplowitz, Neil, additional, Lucena, M. Isabel, additional, Andrade, Raúl J., additional, Andrade, R.J., additional, Lucena, M.I., additional, Stephens, C., additional, Cortés, M. García, additional, Robles-Díaz, M., additional, Ortega-Alonso, A., additional, Pinazo, J., additional, Muñoz, B. García, additional, Alcántara, R., additional, Hernández, A., additional, Escaño, M.D. García, additional, del Campo, E., additional, Medina-Cáliz, I., additional, Sanabria-Cabrera, J., additional, González-Jiménez, A., additional, Sanjuán-Jiménez, R., additional, Cueto, A., additional, Álvarez-Álvarez, I., additional, Bonilla, E., additional, Di Zeo, D., additional, Niu, H., additional, Villanueva, M., additional, Papineau, A., additional, Pérez, M. Jiménez, additional, Grande, R. González, additional, Ortega, S. López, additional, Santaella, I., additional, Ocaña, A., additional, Palomino, P., additional, Fernández, M.C., additional, Peláez, G., additional, Porcel, A., additional, Casado, M., additional, Sánchez, M. González, additional, Romero-Gómez, M., additional, Millán-Domínguez, R., additional, Fombuena, B., additional, Gallego, R., additional, Ampuero, J., additional, Campo, J.A. del, additional, Calle-Sanz, R., additional, Rojas, L., additional, Rojas, A., additional, Gómez, A. Gil, additional, Vilar, E., additional, Soriano, G., additional, Guarner, C., additional, Román, E.M., additional, Manuitt, M.A. Quijada, additional, Arbos, R.M. Antonijoan, additional, Delgado, J. Sánchez, additional, Gómez, M. Vergara, additional, Hallal, H., additional, Oltra, E. García, additional, Arcos, J.C. Titos, additional, Martínez, A. Pérez, additional, Cobarro, C. Sánchez, additional, Caparrós, J.M. Egea, additional, Castiella, A., additional, Zapata, E., additional, Arenas, J., additional, García, A. Gómez, additional, Esandi, F.J., additional, Blanco, S., additional, Odriozola, P. Martínez, additional, Crespo, J., additional, Iruzubieta, P., additional, Cabezas, J., additional, Gallego, A. Giráldez, additional, Rodríguez Seguel, E. del P., additional, Cuaresma, M., additional, Gallego, J. González, additional, Jorquera, F., additional, Campos, S. Sánchez, additional, Otazua, P., additional, de Juan Gómez, A., additional, Salmerón, J., additional, Gila, A., additional, Quiles, R., additional, González, J.M., additional, Lorenzo, S., additional, Prieto, M., additional, Amiel, I. Conde, additional, Berenguer, M., additional, García-Eliz, M., additional, Primo, J., additional, Molés, J.R., additional, Garayoa, A., additional, Carrascosa, M., additional, Domínguez, E. Gómez, additional, Cuevas, L., additional, Farré, M., additional, Montané, E., additional, Barriocanal, A.M., additional, Arellano, A.L., additional, Sanz, Y., additional, Morillas, R.M., additional, Sala, M., additional, Ridaura, H. Masnou, additional, Bruguera, M., additional, Gines, P., additional, Lens, S., additional, García, J.C., additional, Mariño, Z., additional, Guerra, M. Hernández, additional, Sanfiel, J.M. Moreno, additional, Fernández del Campo, C. Boada, additional, Tejedor, M., additional, Ferrer, R. González, additional, Fernández, C., additional, Gil, M. Fernández, additional, Montero, J.L., additional, Mata, M. de la, additional, Olmo, J. Fuentes, additional, Bonilla, E.M. Fernández, additional, Moreno, J.M., additional, Martínez-Rodenas, P., additional, Garrido, M., additional, Oliva, C., additional, Rendón, P., additional, Samaniego, J. García, additional, Madejón, A., additional, Calleja, J.L., additional, Porras, J.L. Martínez, additional, Cabriada, J.L., additional, Pérez-Moreno, J.M., additional, and Lara, C., additional

Published
2021
Full Text
View/download PDF

14. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old

Author

Weersink, R.A., Alvarez-Alvarez, I., Medina-Caliz, I., Sanabria-Cabrera, J., Robles-Diaz, M., Ortega-Alonso, A., Garcia-Cortes, M., Bonilla, E., Niu, H., Soriano, G., Jimenez-Perez, M., Hallal, H., Blanco, S., Kaplowitz, N., Lucena, M.I., Andrade, R.J., Weersink, R.A., Alvarez-Alvarez, I., Medina-Caliz, I., Sanabria-Cabrera, J., Robles-Diaz, M., Ortega-Alonso, A., Garcia-Cortes, M., Bonilla, E., Niu, H., Soriano, G., Jimenez-Perez, M., Hallal, H., Blanco, S., Kaplowitz, N., Lucena, M.I., and Andrade, R.J.

Abstract

Contains fulltext : 236538.pdf (Publisher’s version ) (Closed access), Older patients with hepatotoxicity have been scarcely studied in idiosyncratic drug-induced liver injury (DILI) cohorts. We sought the distinctive characteristics of DILI in older patients across age groups. A total of 882 DILI patients included in the Spanish DILI Registry (33% >/= 65 years) were categorized according to age: "young" (< 65 years); "young-old" (65-74 years); "middle-old" (75-84 years); and "oldest-old" (>/= 85 years). All elderly groups had an increasingly higher comorbidity burden (P < 0.001) and polypharmacy (P < 0.001). There was a relationship between jaundice and hospitalization (P < 0.001), and both were more prevalent in the older age groups, especially in the oldest-old (88% and 69%, respectively), and the DILI episode was more severe (P = 0.029). The proportion of females decreased across age groups from the young to the middle-old, yet in the oldest-old there was a distinct female predominance. Pattern of liver injury shifted towards cholestatic with increasing age among top culprit drugs amoxicillin-clavulanate, atorvastatin, levofloxacin, ibuprofen, and ticlopidine. The best cutoff point for increased odds of cholestatic DILI was 65 years. Older patients had increased non-liver-related mortality (P = 0.030) as shown by the predictive capacity of the Model for End-Stage Liver Disease score (odds ratio (OR) = 1.116; P < 0.001), and comorbidity burden (OR = 4.188; P = 0.001) in the 6-month mortality. Older patients with DILI exhibited an increasingly predominant cholestatic phenotype across a range of culprit drugs, other than amoxicillin-clavulanate, with increased non-liver-related mortality and require a different approach to predict outcome. The oldest DILI patients exhibited a particular phenotype with more severe DILI episodes and need to be considered when stratifying older DILI populations.

Published
2021

15. Microbiota insights in clostridium difficile infection and inflammatory bowel disease

Author

Rodríguez, C., Romero, E., Garrido-Sanchez, L., Alcaín-Martínez, G., Andrade, R.J., Taminiau, B., Daube, G., García-Fuentes, E., [Rodríguez,C, Romero,E, Garrido-Sanchez,L, Alcaín-Martínez,G, Andrade,RJ, García-Fuentes,E] Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain. [Rodríguez,C, García-Fuentes,E] Unidad de Gestión Clínica de Aparato Digestivo, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Garrido-Sanchez,L] Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Andrade,RJ] Department of Medicine and Dermatology, Universidad de Málaga, Málaga, Spain. [Andrade,RJ] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Málaga, Spain. [Taminiau,B, and Daube,G] Fundamental and Applied Research for Animals & Health (FARAH), Department of Food Microbiology, Faculty of Veterinary Medicine, University of Liège, Liège, Belgium.

Subjects
Microbial metabolites, Enfermedades inflamatorias del intestino, Clostridioides difficile, Microbiota, Phenomena and Processes::Metabolic Phenomena::Metabolism::Metabolic Networks and Pathways [Medical Subject Headings], Phenomena and Processes::Physiological Phenomena::Physiological Processes::Growth and Development::Growth::Cell Growth Processes::Cell Proliferation [Medical Subject Headings], Interactions, Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Colonic Diseases::Colitis::Colitis, Ulcerative [Medical Subject Headings], Microbial communities, digestive system, digestive system diseases, Inflammatory bowel disease, Diseases::Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Enterocolitis [Medical Subject Headings], Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Phenomena and Processes::Microbiological Phenomena::Microbiota [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Digestive::Diarrhea [Medical Subject Headings], C. difficile, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Dysbiosis [Medical Subject Headings], Anatomy::Digestive System::Gastrointestinal Tract::Intestines [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings], Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [Medical Subject Headings]
Abstract

Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation that includes Crohn´s disease (CD) and ulcerative colitis (UC). Although the etiology is still unknown, some specific factors have been directly related to IBD, including genetic factors, abnormal intestinal immunity, and/or gut microbiota modifications. Recent findings highlight the primary role of the gut microbiota closely associated with a persistent inappropriate inflammatory response. This gut environment of dysbiosis in a susceptible IBD host can increasingly worsen and lead to colonization and infection with some opportunistic pathogens, especially Clostridium difficile. C. difficile is an intestinal pathogen considered the main cause of antibiotic-associated diarrhea and colitis and an important complication of IBD, which can trigger or worsen an IBD flare. Recent findings have highlighted the loss of bacterial cooperation in the gut ecosystem, as well as the pronounced intestinal dysbiosis, in patients suffering from IBD and concomitant C. difficile infection (CDI). The results of intestinal microbiota studies are still limited and often difficult to compare because of the variety of disease conditions. However, these data provide important clues regarding the main modifications and interrelations in the complicated gut ecosystem to better understand both diseases and to take advantage of the development of new therapeutic strategies. In this review, we analyze in depth the gut microbiota changes associated with both forms of IBD and CDI and their similarity with the dysbiosis that occurs in CDI. We also discuss the metabolic pathways that favor the proliferation or decrease in several important taxa directly related to the disease. Yes

Published
2020

16. Clinical Characteristics and Outcome of Drug‐Induced Liver Injury in the Older Patients: From the Young‐Old to the Oldest‐Old

Author

Weersink, Rianne A., primary, Alvarez‐Alvarez, Ismael, additional, Medina‐Cáliz, Inmaculada, additional, Sanabria‐Cabrera, Judith, additional, Robles‐Díaz, Mercedes, additional, Ortega‐Alonso, Aida, additional, García‐Cortés, Miren, additional, Bonilla, Elvira, additional, Niu, Hao, additional, Soriano, German, additional, Jimenez‐Perez, Miguel, additional, Hallal, Hacibe, additional, Blanco, Sonia, additional, Kaplowitz, Neil, additional, Lucena, M. Isabel, additional, Andrade, Raúl J., additional, Andrade, R.J., additional, Lucena, M.I., additional, Stephens, C., additional, García Cortés, M., additional, Robles Díaz, M., additional, Ortega Alonso, A., additional, Pinazo, J., additional, García Muñoz, B., additional, Alcántara, R., additional, Hernández, A., additional, García‐Escaño, M.D., additional, Medina‐Cáliz, I., additional, Sanabria‐Cabrera, J., additional, Alvarez‐Alvarez, I., additional, Bonilla, E., additional, Niu, H., additional, Di‐Zeo, D., additional, Del Campo, E., additional, Jiménez Pérez, M., additional, González Grande, R., additional, López Ortega, S., additional, Santaella, I., additional, Ocaña, A., additional, Palomino, P., additional, Fernández, M.C., additional, Porcel, A., additional, Casado, M., additional, González Sánchez, M., additional, Romero‐Gómez, M., additional, Millán‐Domínguez, R., additional, Fombuena, B., additional, Gallego, R., additional, Ampuero, J., additional, del Campo, J.A., additional, Calle‐Sanz, R., additional, Rojas, L., additional, Rojas, A., additional, Gil Gómez, A., additional, Vilar, E., additional, Soriano, G., additional, Guarner, C., additional, Román, E.M., additional, Quijada Manuitt, M.A., additional, Antonijoan Arbos, R.M., additional, Farré, M., additional, Montané, E., additional, Arellano, A.L., additional, Barriocanal, A.M., additional, Sanz, Y., additional, Morillas, R.M., additional, Sala, M., additional, Masnou Ridaura, H., additional, Sánchez Delgado, J., additional, Vergara Gómez, M., additional, Hallal, H., additional, García Oltra, E., additional, Titos Arcos, J.C., additional, Pérez Martínez, A., additional, Sánchez Cobarro, C., additional, Egea Caparrós, J.M., additional, Castiella, A., additional, Arenas, J., additional, Gomez Osua, M.I., additional, Gómez García, A., additional, Esandi, F.J., additional, Blanco, S., additional, Martínez Odriozola, P., additional, Crespo, J., additional, Iruzubieta, P., additional, Cabezas, J., additional, Giráldez Gallego, A., additional, Rodríguez Seguel, E. del P., additional, Cuaresma, M., additional, Prieto, M., additional, Conde Amiel, I., additional, Berenguer, M., additional, García‐Eliz, M., additional, Moreno, J.M., additional, Martínez‐Rodenas, P., additional, Garrido, M., additional, Oliva, C., additional, Gómez Domínguez, E., additional, Cabrera, L., additional, Cuevas, L., additional, Bruguera, M., additional, Gines, P., additional, Lens, S., additional, García, J.C., additional, Mariño, Z., additional, Hernández Guerra, M., additional, Moreno San Fiel, M., additional, Boada Fernández del Campo, C., additional, Fuentes Olmo, J., additional, Fernández Bonilla, E.M., additional, Jorquera, F., additional, and González Gallego, J., additional

Published
2020
Full Text
View/download PDF

20. Clinical Characteristics and Outcome of Drug‐Induced Liver Injury in the Older Patients: From the Young‐Old to the Oldest‐Old.

Author

Weersink, Rianne A., Alvarez‐Alvarez, Ismael, Medina‐Cáliz, Inmaculada, Sanabria‐Cabrera, Judith, Robles‐Díaz, Mercedes, Ortega‐Alonso, Aida, García‐Cortés, Miren, Bonilla, Elvira, Niu, Hao, Soriano, German, Jimenez‐Perez, Miguel, Hallal, Hacibe, Blanco, Sonia, Kaplowitz, Neil, Lucena, M. Isabel, Andrade, Raúl J., Andrade, R.J., Lucena, M.I., Stephens, C., and García Cortés, M.

Subjects
OLDER patients, TREATMENT effectiveness, LIVER injuries, AGE groups, COMORBIDITY, HEPATOTOXICOLOGY, PHENOTYPES
Abstract

Older patients with hepatotoxicity have been scarcely studied in idiosyncratic drug‐induced liver injury (DILI) cohorts. We sought the distinctive characteristics of DILI in older patients across age groups. A total of 882 DILI patients included in the Spanish DILI Registry (33% ≥ 65 years) were categorized according to age: "young" (< 65 years); "young‐old" (65–74 years); "middle‐old" (75–84 years); and "oldest‐old" (≥ 85 years). All elderly groups had an increasingly higher comorbidity burden (P < 0.001) and polypharmacy (P < 0.001). There was a relationship between jaundice and hospitalization (P < 0.001), and both were more prevalent in the older age groups, especially in the oldest‐old (88% and 69%, respectively), and the DILI episode was more severe (P = 0.029). The proportion of females decreased across age groups from the young to the middle‐old, yet in the oldest‐old there was a distinct female predominance. Pattern of liver injury shifted towards cholestatic with increasing age among top culprit drugs amoxicillin‐clavulanate, atorvastatin, levofloxacin, ibuprofen, and ticlopidine. The best cutoff point for increased odds of cholestatic DILI was 65 years. Older patients had increased non–liver‐related mortality (P = 0.030) as shown by the predictive capacity of the Model for End‐Stage Liver Disease score (odds ratio (OR) = 1.116; P < 0.001), and comorbidity burden (OR = 4.188; P = 0.001) in the 6‐month mortality. Older patients with DILI exhibited an increasingly predominant cholestatic phenotype across a range of culprit drugs, other than amoxicillin‐clavulanate, with increased non–liver‐related mortality and require a different approach to predict outcome. The oldest DILI patients exhibited a particular phenotype with more severe DILI episodes and need to be considered when stratifying older DILI populations. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years

Author

Reig, A., primary, Llovet, L.P., additional, Gomez, M.R., additional, Sáez-Royuela, F., additional, Fábrega, E., additional, Salmerón, J., additional, Horta, D., additional, Castano-Garcia, A., additional, Albillos, A., additional, Andrade, R.J., additional, Sala, M., additional, Carrión, J.A., additional, Domínguez, E.G., additional, Chahri, N., additional, Conde, I., additional, Moya, A.G., additional, Conde, M.H., additional, Diago, M., additional, and Pares, A., additional

Published
2018
Full Text
View/download PDF

22. DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome

Author

Medina-Caliz, I., primary, Almarza, M., additional, Stephens, C., additional, Robles-Díaz, M., additional, Sanabria-Cabrera, J., additional, Gonzalez-Jimenez, A., additional, Sanjuan-Jimenez, Rocío, additional, Ortega-Alonso, A., additional, Cortes, M.G., additional, García-Muñoz, B., additional, Quiros-Cano, M., additional, Martin-Reyes, F., additional, Cueto, A., additional, Fernández, M., additional, Ginès, P., additional, Gomez, M.R., additional, Soriano, G., additional, Prieto, M., additional, Conde, I., additional, Bessone, F., additional, Hernandez, N., additional, Arrese, M., additional, Cabello, M., additional, Lucena, M.I., additional, and Andrade, R.J., additional

Published
2018
Full Text
View/download PDF

23. Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry

Author

Ampuero, J., primary, Aller, R., additional, Gallego-Durán, R., additional, Banales, J., additional, Crespo, J., additional, Mora-Cuadrado, N., additional, Garcia-Monzon, C., additional, Pareja, M.J., additional, Vilar-Gomez, E., additional, Jiménez-Agüero, R., additional, Caballería, J., additional, Loste, M.T.A., additional, Escudero-García, D., additional, Gómez-Camarero, J., additional, Panero, J.L.C., additional, De Luis Román, D.A., additional, Gónzalez-Rodriguez, Á., additional, Latorre, M., additional, Albillos, A., additional, Aguilar-Urbano, V., additional, Salmerón, J., additional, Olcoz-Goñi, J.L., additional, Aspichueta, P., additional, Santos-Laso, Á., additional, Iacono, O.L., additional, Iruzubieta, P., additional, Graupera, I., additional, García-Torres, M., additional, Badia-Aranda, E., additional, Guerra, J.A., additional, Francés, R., additional, Pastor, H., additional, Pozo-Maroto, E.D., additional, Diago, M., additional, Martin-Mateos, R., additional, Benlloch, S., additional, Fernández-Rodríguez, C., additional, Rey, F.J.G.-S., additional, Estevez, P., additional, Andrade, R.J., additional, Turnés, J., additional, and Gomez, M.R., additional

Published
2018
Full Text
View/download PDF

24. Hepamet Score: a new non-invasive method for NAFLD-related fibrosis screening in clinical practice

Author

Ampuero, J., primary, Aller, Rocío, additional, Gallego-Durán, Rocío, additional, Banales, Jesús, additional, Crespo, J., additional, Vilar-Gomez, E., additional, Petta, S., additional, Garcia-Monzon, C., additional, Mora-Cuadrado, N., additional, Castellanos-Fernandez, M., additional, Craxi, A., additional, Pareja, María Jesús, additional, Jiménez-Agüero, Raúl, additional, Caballería, J., additional, Loste, María T.A., additional, Escudero-García, D., additional, Gómez-Camarero, J., additional, Panero, José L.C., additional, De Luis Román, D.A., additional, Fabian, L.G., additional, Di Marco, V., additional, Gónzalez-Rodriguez, Águeda, additional, Latorre, M., additional, Albillos, A., additional, Aguilar-Urbano, Victor, additional, Salmerón, J., additional, Olcoz-Goñi, José L., additional, Aspichueta, P., additional, Santos-Laso, Álvaro, additional, Lo Iacono, O., additional, Iruzubieta, P., additional, Graupera, I., additional, García-Torres, M., additional, Badia-Aranda, E., additional, Guerra, J.A., additional, Francés, Rubén, additional, Pastor, H., additional, Del Pozo-Maroto, E., additional, Diago, M., additional, Martin-Mateos, R., additional, Benlloch, S., additional, Fernández-Rodríguez, C., additional, Rey, F.J.G.-S., additional, Estevez, P., additional, Andrade, R.J., additional, Turnés, J., additional, and Gomez, M.R., additional

Published
2018
Full Text
View/download PDF

25. Independent cohort validation of hepatic metabolism, daily dose and comorbidities as features associated with delayed symptom onset in drug-induced liver injury

Author

González-Jiménez, A., primary, Medina-Caliz, I., additional, Robles-Díaz, M., additional, Bessone, F., additional, Hernandez, N., additional, Sánchez, A., additional, Arrese, M., additional, Filho, R.P., additional, Lizarzábal, M., additional, Tagle, M., additional, Lucena, M.I., additional, Stephens, C., additional, and Andrade, R.J., additional

Published
2018
Full Text
View/download PDF

26. Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity

Author

Ampuero, J., primary, Aller, R., additional, Gallego-Durán, R., additional, Banales, J., additional, Crespo, J., additional, Mora-Cuadrado, N., additional, Garcia-Monzon, C., additional, Pareja, M.J., additional, Vilar-Gomez, E., additional, Jiménez-Agüero, R., additional, Caballería, J., additional, Loste, M.T.A., additional, Escudero-García, D., additional, Gómez-Camarero, J., additional, Panero, J.L.C., additional, De Luis Román, D.A., additional, Gónzalez-Rodriguez, Á., additional, Latorre, M., additional, Albillos, A., additional, Aguilar-Urbano, V., additional, Salmerón, J., additional, Olcoz-Goñi, J.L., additional, Aspichueta, P., additional, Santos-Laso, Á., additional, Iacono, O.L., additional, Iruzubieta, P., additional, Graupera, I., additional, García-Torres, M., additional, Badia-Aranda, E., additional, Guerra, J.A., additional, Francés, R., additional, Pastor, H., additional, Pozo-Maroto, E.D., additional, Diago, M., additional, Martin-Mateos, R., additional, Benlloch, S., additional, Fernández-Rodríguez, C., additional, Rey, F.J.G.-S., additional, Estevez, P., additional, Andrade, R.J., additional, Turnés, J., additional, and Gomez, M.R., additional

Published
2018
Full Text
View/download PDF

27. Genetic and functional analysis of FGF21 in NAFLD/NASH

Author

Gallego-Durán, R., primary, Martin, F., additional, Ampuero, J., additional, Castillo, J.A.D.C., additional, Pastor, H., additional, Pareja, M.J., additional, Gil-Gomez, A., additional, Rojas, A., additional, Carmen Rico, M., additional, Millan, R., additional, Montero-Vallejo, R., additional, Alvarez-Amor, L., additional, Loste, M.T.A., additional, Guerra, J.A., additional, Hernandez, R.M., additional, Panero, J.L.C., additional, Andrade, R.J., additional, Crespo, J., additional, García-Monzón, C., additional, and Gomez, M.R., additional

Published
2018
Full Text
View/download PDF

28. Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis

Author

Ferret, M.B., primary, Pineda, J., additional, Panero, J.L.C., additional, Rodríguez, M., additional, Morillas, R.M., additional, Pascasio, J.M., additional, Rivero, A., additional, Mcnabb, B., additional, Zhang, G., additional, Camus, G., additional, Stamm, L., additional, Brainard, D., additional, Subramanian, M., additional, Carrión, J.A., additional, Andrade, R.J., additional, Amado, L.E.M., additional, Turnés, J., additional, Lens, S., additional, Casado, M., additional, and Esteban, R., additional

Published
2018
Full Text
View/download PDF

29. Expert clinical management of autoimmune hepatitis in the real world

Author

Liberal, R., Boer, Y.S. de, Andrade, R.J., Bouma, G., Dalekos, G.N., Floreani, A., Gleeson, D., Hirschfield, G.M., Invernizzi, P., Lenzi, M., Lohse, A.W., Macedo, G., Milkiewicz, P., Terziroli, B., Hoek, B. van, Vierling, J.M., Heneghan, M.A., Drenth, J.P., et al., Liberal, R., Boer, Y.S. de, Andrade, R.J., Bouma, G., Dalekos, G.N., Floreani, A., Gleeson, D., Hirschfield, G.M., Invernizzi, P., Lenzi, M., Lohse, A.W., Macedo, G., Milkiewicz, P., Terziroli, B., Hoek, B. van, Vierling, J.M., Heneghan, M.A., Drenth, J.P., and et al.

Abstract

Item does not contain fulltext, BACKGROUND: High-quality data on the management of autoimmune hepatitis (AIH) are scarce. Despite published guidelines, management of AIH is still expert based rather than evidence based. AIM: To survey expert hepatologists, asking each to describe their practices in the management of patients with AIH. METHODS: A survey questionnaire was distributed to members of the International AIH Group. The questionnaire consisted of four clinical scenarios on different presentations of AIH. RESULTS: Sixty surveys were sent, out of which 37 were returned. None reported budesonide as a first line induction agent for the acute presentation of AIH. Five (14%) participants reported using thiopurine S-methyltransferase measurements before commencement of thiopurine maintenance therapy. Thirteen (35%) routinely perform liver biopsy at 2 years of biochemical remission. If histological inflammatory activity is absent, four (11%) participants reduced azathioprine, whereas 10 (27%) attempted withdrawal altogether. Regarding the management of difficult-to-treat patients, mycophenolate mofetil is the most widely used second-line agent (n = ~450 in 28 centres), whereas tacrolimus (n = ~115 in 21 centres) and ciclosporin (n = ~112 in 18 centres) are less often reported. One centre reported considerable experience with infliximab, while rescue therapy with rituximab has been tried in seven centres. CONCLUSIONS: There is a wide variation in the management of patients with autoimmune hepatitis even among the most expert in the field. Although good quality evidence is lacking, there is considerable experience with second-line therapies. Future prospective studies should address these issues, so that we move from an expert- to an evidence- and personalised-based care in autoimmune hepatitis.

Published
2017

33. Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD

Author

Gómez, E.V., primary, Aller, R., additional, Gallego-Durán, R., additional, Bañales, J., additional, Loste, M.T.A., additional, García-Monzón, C., additional, Ramirez, H.P., additional, García-Torres, M.L., additional, Gómez-Camarero, J., additional, Caballería, J., additional, Aguilar-Urbano, V., additional, Salmerón, J., additional, Calleja, J.L., additional, Abad, J., additional, Olcoz-Goñi, J.L., additional, Albillos, A., additional, Diago, M., additional, Iacono, O.L., additional, Francés, R., additional, Fernández-Rodríguez, C.M., additional, García-Samaniego, J., additional, Benlloch, S., additional, Aspichueta, P., additional, Andrade, R.J., additional, Ampuero, J., additional, Bertot, L.C., additional, Adams, L.A., additional, and Romero-Gómez, M., additional

Published
2017
Full Text
View/download PDF

34. Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice

Author

Ruiz-Antorán, B., primary, Rincón, D., additional, Conde, M.H., additional, Fernández, I., additional, García-Samaniego, J., additional, Gea, F., additional, Cabezas, J., additional, Sacristán, B., additional, Jorquera, F., additional, Turnes, J., additional, Prieto, M., additional, Llaneras, J., additional, Pascasio, J.M., additional, Royuela, F.S., additional, Lens, S., additional, Serra, M.A., additional, Morillas, R.M., additional, Torras, X., additional, Andrade, R.J., additional, Bermejo, M.F., additional, Ampuero, J., additional, Molina, E., additional, Bonet, L., additional, Diago, M., additional, Salcines, J.R., additional, Moreno, J.M., additional, Crespo, J., additional, and Panero, J.L.C., additional

Published
2017
Full Text
View/download PDF

35. Adherence to SmPC recommendations in real-world practice in the treatment of monoinfected patients with chronic genotype 1 or 4 HCV infection with direct-acting antivirals

Author

Ruiz-Antorán, B., primary, Rincón, D., additional, Perelló, C., additional, Fernandez, I., additional, Gea, F., additional, Mariño, Z., additional, García-Samaniego, J., additional, Hontangas, V., additional, Cabezas, J., additional, Sacristan, B., additional, Pascasio, J.M., additional, Morillas, R.M., additional, Turnes, J., additional, Llaneras, J., additional, Serra, M.A., additional, Torras, X., additional, Diago, M., additional, Jorquera, F., additional, Fernández, C., additional, Simón, M.A., additional, Bermejo, M.F., additional, Ruano, J.J.S., additional, Arenas, J., additional, Andrade, R.J., additional, Ampuero, J., additional, Bonet, L., additional, Crespo, J., additional, and Panero, J.L.C., additional

Published
2017
Full Text
View/download PDF

36. Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry

Author

Slim, M., primary, Sanabria, J., additional, Robles-Díaz, M., additional, Medina-Cáliz, I., additional, González-Jiménez, A., additional, Ortega, A., additional, García-Cortés, M., additional, Garcia-Muñoz, B., additional, Sanjuán-Jiménez, R., additional, Fernandez, M.C., additional, Castiella, A., additional, Zapata, E., additional, Hallal, H., additional, Montane, E., additional, Soriano, G., additional, Roman, E., additional, Navarro, J.M., additional, Jimenez, M., additional, Prieto, M., additional, Conde, I., additional, Aldea, A., additional, Hernández-Guerra, M., additional, Moreno, J.M., additional, Romero-Gomez, M., additional, Gomez-Dominguez, E., additional, Lucena, M.I., additional, and Andrade, R.J., additional

Published
2017
Full Text
View/download PDF

37. Comparison of cytokine profiles in idiosyncratic drug-induced liver injury, acute non-drug-induced hepatitis and controls

Author

Stephens, C., primary, Sanjuan-Jiménez, R., additional, Sanabria-Cabrera, J.A., additional, Battikhi, B., additional, Ortega-Alonso, A., additional, Robles-Díaz, M., additional, Jiménez-Pérez, M., additional, Medina-Cáliz, I., additional, Ruiz-Cabello, F., additional, Lucena, M.I., additional, and Andrade, R.J., additional

Published
2017
Full Text
View/download PDF

38. Creating an effective clinical registry for rare diseases

Author

D'Agnolo, H.M.A., Kievit, W., Andrade, R.J., Karlsen, T.H., Wedemeyer, H., Drenth, J.P.H., D'Agnolo, H.M.A., Kievit, W., Andrade, R.J., Karlsen, T.H., Wedemeyer, H., and Drenth, J.P.H.

Abstract

Contains fulltext : 172236.pdf (publisher's version ) (Closed access), The exposure of clinicians to patients with rare gastrointestinal diseases is limited. This hurts clinical studies, which impedes accumulation of scientific knowledge on the natural disease course, treatment outcomes and prognosis in these patients. An excellent method to detect patterns on an aggregate level that would not be possible to discover in individual cases, is a registry study. This paper aims to describe a template to create a successful international registry for rare diseases. We focus mainly on rare hepatic diseases, but lessons from this paper serve other fields in medicine, as well.

Published
2016

41. Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Author

Ratziu, Vlad, primary, Harrison, Stephen A., additional, Francque, Sven, additional, Bedossa, Pierre, additional, Lehert, Philippe, additional, Serfaty, Lawrence, additional, Romero-Gomez, Manuel, additional, Boursier, Jérôme, additional, Abdelmalek, Manal, additional, Caldwell, Steve, additional, Drenth, Joost, additional, Anstee, Quentin M., additional, Hum, Dean, additional, Hanf, Remy, additional, Roudot, Alice, additional, Megnien, Sophie, additional, Staels, Bart, additional, Sanyal, Arun, additional, Mathurin, P., additional, Gournay, J., additional, Nguyen-Khac, E., additional, De Ledinghen, V., additional, Larrey, D., additional, Tran, A., additional, Bourliere, M., additional, Maynard-Muet, M., additional, Asselah, T., additional, Henrion, J., additional, Nevens, F., additional, Cassiman, D., additional, Geerts, A., additional, Moreno, C., additional, Beuers, U.H., additional, Galle, P.R., additional, Spengler, U., additional, Bugianesi, E., additional, Craxi, A., additional, Angelico, M., additional, Fargion, S., additional, Voiculescu, M., additional, Gheorghe, L., additional, Preotescu, L., additional, Caballeria, J., additional, Andrade, R.J., additional, Crespo, J., additional, Callera, J.L., additional, Ala, A., additional, Aithal, G., additional, Abouda, G., additional, Luketic, V., additional, Huang, M.A., additional, Gordon, S., additional, Pockros, P., additional, Poordad, F., additional, Shores, N., additional, Moehlen, M.W., additional, Bambha, K., additional, Clark, V., additional, Satapathy, S., additional, Parekh, S., additional, Reddy, R.K., additional, Sheikh, M.Y., additional, Szabo, G., additional, Vierling, J., additional, Foster, T., additional, Umpierrez, G., additional, Chang, C., additional, Box, T., additional, and Gallegos-Orozco, J., additional

Published
2016
Full Text
View/download PDF

45. Clinical Management of Autoimmune Hepatitis in the Real World

Author

Liberal, R., primary, de Boer, Y., additional, Andrade, R.J., additional, Bouma, G., additional, Dalekos, G.N., additional, Floreani, A., additional, Gleeson, D., additional, Hirschfield, G., additional, Invernizzi, P., additional, Lenzi, M., additional, Lohse, A., additional, Macedo, G., additional, Milkiewicz, P., additional, Terziroli, B., additional, van Hoek, B., additional, Vierling, J., additional, and Heneghan, M.A., additional

Published
2016
Full Text
View/download PDF

46. Hepatotoxicity Associated with Non-Steroidal Anti-Inflammatory Drugs. A Comparative Analysis among Ibuprofen, Diclofenac and Nimesulide fromthe Spanish and Latin-American Dili Registries

Author

Gonzalez-Jimenez, A., primary, Medina-Cáliz, I., additional, Robles-Díaz, M., additional, Zoubek, M.E., additional, Díaz-Jimenez, P., additional, Cabello, M.R., additional, Ortega-Alonso, A., additional, García-Cortes, M., additional, García-Muñoz, B., additional, Fernandez, M.C., additional, Slim, M., additional, Romero-Gómez, M., additional, Bessone, F., additional, Hernandez, N., additional, Arrese, M., additional, Montane, E., additional, Hallal, H., additional, Sanabria-Cabrera, J.A., additional, Sanjuan-Jimenez, R., additional, Lucena, M.I., additional, and Andrade, R.J., additional

Published
2016
Full Text
View/download PDF

47. The FTO rs1421085 T > C Polymorphism is Associated with the Severity of Non-Alcoholic Fatty Liver

Author

Loste, M.T.A., primary, Gallego-Duran, R., additional, Alonso, C., additional, Iruzubieta, P., additional, Ampuero, J., additional, Ramos, D., additional, Gil-Gomez, A., additional, Abad, J., additional, Fábrega, E., additional, Calleja, J.L., additional, Andrade, R.J., additional, García-Monzón, C., additional, Romero-Gomez, M., additional, and Crespo, J., additional

Published
2016
Full Text
View/download PDF

48. Impact of GWAS-Identified Common Variants on Histopathological Features of Non-Alcoholic Fatty Liver Disease Patients

Author

Gallego-Durán, R., primary, Ampuero, J., additional, Del Campo, J.A., additional, Pastor-Ramírez, H., additional, Vilar-Gomez, E., additional, Gil-Gómez, A., additional, Arias-Loste, M.T., additional, Pareja, M.J., additional, Abad, J., additional, Rico, M.C., additional, García-Valdecasas, M., additional, Moreno, I., additional, Calleja, J.L., additional, Andrade, R.J., additional, Crespo, J., additional, García-Monzón, C., additional, and Romero-Gómez, M., additional

Published
2016
Full Text
View/download PDF

49. SAT-507 - Metabolically unhealthy status impacts on the risk of significant liver injury in biopsy-proven NAFLD patients beyond obesity

Author

Ampuero, J., Aller, R., Gallego-Durán, R., Banales, J., Crespo, J., Mora-Cuadrado, N., Garcia-Monzon, C., Pareja, M.J., Vilar-Gomez, E., Jiménez-Agüero, R., Caballería, J., Loste, M.T.A., Escudero-García, D., Gómez-Camarero, J., Panero, J.L.C., De Luis Román, D.A., Gónzalez-Rodriguez, Á., Latorre, M., Albillos, A., Aguilar-Urbano, V., Salmerón, J., Olcoz-Goñi, J.L., Aspichueta, P., Santos-Laso, Á., Iacono, O.L., Iruzubieta, P., Graupera, I., García-Torres, M., Badia-Aranda, E., Guerra, J.A., Francés, R., Pastor, H., Pozo-Maroto, E.D., Diago, M., Martin-Mateos, R., Benlloch, S., Fernández-Rodríguez, C., Rey, F.J.G.-S., Estevez, P., Andrade, R.J., Turnés, J., and Gomez, M.R.

Published
2018
Full Text
View/download PDF

50. SAT-508 - Clinical Outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry

Author

Ampuero, J., Aller, R., Gallego-Durán, R., Banales, J., Crespo, J., Mora-Cuadrado, N., Garcia-Monzon, C., Pareja, M.J., Vilar-Gomez, E., Jiménez-Agüero, R., Caballería, J., Loste, M.T.A., Escudero-García, D., Gómez-Camarero, J., Panero, J.L.C., De Luis Román, D.A., Gónzalez-Rodriguez, Á., Latorre, M., Albillos, A., Aguilar-Urbano, V., Salmerón, J., Olcoz-Goñi, J.L., Aspichueta, P., Santos-Laso, Á., Iacono, O.L., Iruzubieta, P., Graupera, I., García-Torres, M., Badia-Aranda, E., Guerra, J.A., Francés, R., Pastor, H., Pozo-Maroto, E.D., Diago, M., Martin-Mateos, R., Benlloch, S., Fernández-Rodríguez, C., Rey, F.J.G.-S., Estevez, P., Andrade, R.J., Turnés, J., and Gomez, M.R.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results